Introduction
Cellular senescence is an important tumor suppression mechanism in vivo (1) . In primary mammalian cells, cellular senescence can be triggered by various inducers including critically shortened telomeres and activated oncogenes (such as oncogenic-RAS) (1) . Senescent cells are viable but non-dividing (2) . Senescent cells also exhibit several distinctive morphological characteristics and molecular markers, including a large flat cellular morphology and expression of senescence-associated β-galactosidase (SA-β-gal) activity (3) . In murine liver carcinoma and sarcoma models, reactivation of the tumor suppressor p53 induces senescence and is associated with tumor regression (4, 5) . Hence, driving cancer cells to undergo cellular senescence represents a novel mechanism for developing cancer therapeutics (6, 7) .
Over 85% of ovarian cancers are of epithelial origin (8) . Epithelial ovarian cancers (EOC) are classified into distinct histological types including serous, mucinous, endometrioid, and clear cell (9) . The most common histology of EOC is serous (~60% of all cancers) and less common histologies include endometrioid, clear cell, and mucinous (9) . Recently, an alternative classification has been proposed, in which EOC is broadly divided into two types (10) . Type I EOC includes endometrioid, mucinous, low-grade serous, and clear cell carcinomas, and type II EOC includes high-grade serous carcinomas (10) . EOC remains the most lethal gynecological malignancy in the United States (8) . Thus, there is an urgent need to better understand the etiology of EOC in order to develop novel therapeutics for this devastating disease.
Wnt signaling is initiated by binding of the Wnt ligand to its cognate Frizzled receptor (11) . Canonical Wnt signaling results in stabilization of the key transcription factor β-catenin, which then translocates into the nucleus and drives expression of its target genes such as CCND1 (cyclin D1), FOSL1 and c-MYC (12, 13) . Canonical Wnt signaling is active in the putative 4 somatic stem/progenitor cells of the coelomic epithelium of the mouse ovary (14) . Underscoring the importance of Wnt signaling in EOC, in a murine ovarian cancer model, activation of canonical Wnt signaling cooperates with inactivation of the tumor suppressor PTEN in driving ovarian carcinogenesis (15) . However, the role of Wnt signaling in EOC is not fully understood.
Wnt5a is a non-canonical Wnt ligand that plays opposing roles in different types of cancer and has variable expression dependent on the cancer context (16) . Specifically, in EOC the role of Wnt5a remains unclear. Thus, in this study, we investigated Wnt5a expression and its potential function in human EOC cells. We discovered that Wnt5a was expressed at significantly lower levels in primary human EOC compared with either primary human ovarian surface epithelium or fallopian tube epithelium. Notably, loss of Wnt5a expression was associated with tumor stage and predicted shorter overall survival in EOC patients.
Significantly, Wnt5a reconstitution inhibited the growth of EOC cells both in vitro and in vivo in
an orthotopic EOC mouse model by promoting cellular senescence. These studies demonstrate, for the first time, a functional role of the non-canonical Wnt ligand, Wnt5a, in promoting senescence. Importantly, they also suggest that promoting EOC cells to undergo senescence represents a potential novel strategy for developing urgently needed EOC therapeutics. 
Materials and Methods
Cells and culture conditions. Primary HOSE cells were isolated and cultured as previously described (17) . Human EOC cell lines were obtained from ATCC and were passaged for fewer than six months. EOC cell line identification was further confirmed by DNA Diagnostic Center (www.dnacenter.com). EOC cell lines were cultured according to ATCC in RPMI1640 medium supplemented with 10% FBS. 5-Aza-cytadine (Sigma) was used at working concentration of 5 μM (18).
Human ovarian specimens and immunohistochemistry. The protocol to evaluate de-identified human tissue specimens was approved by Fox Chase Cancer Center (FCCC) institutional review board (IRB). Ovarian tumor microarray and normal human ovary and fallopian tube specimens were obtained from the FCCC Biosample Repository Core Facility (BRCF). Histopathology of the selected specimens on the tumor microarrays was provided by BRCF. Immunohistochemistry was performed using goat anti-Wnt5a polyclonal antibody (R&D Systems) and mouse anti-Ki67 (Dako) with a Dako Envision Tm + System and the Peroxidase (DAB) kit (DAKO Corporation)
following the manufacturer's instructions and as previously described (17) . Wnt5a staining was scored in a double-blinded manner by Dr. Qi Cai at the BRCF and a proportion of the cases were independently confirmed by Dr. Hong Wu, a board-certified pathologist, at the FCCC Department of Pathology.
Anchorage-independent soft agar colony formation assay. Soft agar assay were performed as previously described (17) . Briefly, 3,500 cells were resuspended in 0.35% low melt agarose 7 Systems), mouse β-actin (Sigma), mouse anti-GAPDH (Millipore), mouse anti-β-catenin, mouse anti-Rb (BD Biosciences), and rabbit anti-pRBpS780 (Cell Signaling).
Immunofluorescence and SA-β-gal staining. Indirect immunofluorescence staining was performed as previously described (19, 20, 22) . The following antibodies were used for immunofluorescence: a cocktail of mouse anti-HIRA monoclonal antibodies (WC19, WC117 and WC119, 1:10) (20) and a rabbit anti-PML antibody (Chemicon, 1:5000). Images were captured using a DS-Qilmc camera on a Nikon Eclipse 80i microscope, and processed using NIS-Elements BR3.0 software (Nikon). SA-β-gal staining was performed as described previously (3, 23) . For SA-β-gal staining in sections from xenografted tumors, eight separate fields were examined from two individual tumors for each of the groups.
In vivo orthotopic xenograft tumorigenesis study. The protocol was approved by the FCCC Institutional Animal Care and Use Committee (IACUC). OVCAR5 cells were infected with a luciferase encoding retrovirus (hygro-pWZL-Luciferase) and infected cells were selected with 50 μg/ml hygromycin. Drug-selected cells were then infected with control or Wnt5a encoding retrovirus and subsequently selected with 3 μg/mL puromycin and 50 μg/mL hygromycin. 3 X 10 6 drug-selected cells were unilaterally injected into the ovarian bursa sac of immunocompromised mice (6 mice per group) (24 Figure 1B ; p = 0.008). Consistently, we observed that Wnt5a protein levels were also lower in human EOC cell lines compared with primary HOSE cells as determined by immunoblotting ( Figure 1C ). Based on these results, we conclude that Wnt5a is expressed at lower levels in human EOC cell lines compared with primary HOSE cells.
We next determined if the loss of Wnt5a expression found in human EOC cell lines was also observed in primary human EOCs. We examined Wnt5a expression in 130 cases of primary human EOC specimens and 31 cases of normal human ovary with surface epithelium by immunohistochemistry (IHC) using an antibody against Wnt5a (Table 1) . Additionally, there is recent evidence to suggest that a proportion of high-grade serous EOC may arise from distant fallopian tube epithelium (25) . Thus, we also included 28 cases of normal human fallopian tube specimens in our IHC analysis ( confirmed in our study ( Figure S1 ). A single band at predicted molecular weight (~ 42 kDa) was detected in OVCAR5 cells with ectopically expressed Wnt5a and was absent after expression of a shRNA to the human Wnt5a gene (shWnt5a), which effectively knocked down Wnt5a mRNA expression ( Figure S1A and data not shown). In addition, Wnt5a staining was lost when primary anti-Wnt5a antibody was replaced with an isotype matched IgG control ( Figure S1B ).
As shown in Figure 1D , in normal human ovarian surface epithelial cells and fallopian tube epithelial cells, both cytoplasm and cell membrane were positive for Wnt5a IHC staining (black arrows, Figure 1D ). In contrast, Wnt5a staining in EOC cells was dramatically decreased ( Figure 1D ). We scored expression of Wnt5a as high (H-score ≥ 30) or low (H-score < 30) based on a histological score (H-score) (26) , which considers both intensity of staining and percentage of positively stained cells, as previously described (17) . Wnt5a expression was scored as high in 58.1% (18/31) cases of normal human ovarian surface epithelium and 82.1% (23/28) cases of normal human fallopian tube epithelium (Table 1 ). In contrast, Wnt5a expression was scored as high in 37.7% (49/130) cases of primary human EOCs (Table 1 ). Statistical analysis revealed that Wnt5a was expressed at significantly lower levels in primary human EOCs compared with either normal human ovarian surface epithelium (p = 0.039) or normal human fallopian tube epithelium (p < 0.001) ( Table 1) . On the basis of these studies, we conclude that Wnt5a is expressed at significantly lower levels in primary human EOCs compared with either normal human ovarian surface epithelium or fallopian tube epithelium. We next examined the correlation between Wnt5a expression and clinical and pathological features of human EOCs. Significantly, there was a negative correlation between Wnt5a expression and tumor stage (p = 0.003) ( Table 1) . Notably, the majority of examined cases are high-grade serous subtypes that are usually of stage 3/4. In addition, we examined the correlation between expression of Wnt5a and a marker of cell proliferation, Ki67 (27) ( Figure   1E ). There was a significant negative correlation between Wnt5a expression and Ki67 (p = 0.038) ( Table 1) . We next assessed whether Wnt5a expression based on H-score might predict prognosis of EOC patients (High, H-score ≥ 30; Low, H-score < 30) (n = 123), for which longterm follow-up data were available. Significantly, lower Wnt5a expression correlated with shorter overall survival in the examined EOC patients (p = 0.003) ( Figure 1F ). Together, we conclude that a lower level of Wnt5a expression correlates with tumor stage and predicts shorter overall survival in human EOC patients.
Wnt5a gene promoter hypermethylation contributes to its downregulation in human EOC

cells.
Wnt5a gene promoter hypermethylation has been implicated as a mechanism underlying its silencing in several types of human cancers (16) . Consistently, we also observed Wnt5a gene promoter hypermethylation in a number of human EOC cell lines ( Figure 2A and Table S1 ).
Further supporting a role of promoter hypermethylation in suppression of Wnt5a expression, treatment with a DNA demethylation drug, 5-Aza-cytadine (28), in PEO1 EOC cells resulted in a significant increase in levels of both Wnt5a mRNA and protein ( Figure 2B-C) . We conclude that Wnt5a gene promoter hypermethylation contributes to its downregulation in human EOC cells. Canonical Wnt signaling promotes cell proliferation and Wnt5a has been demonstrated to antagonize the canonical Wnt/ β-catenin signaling in certain cell contexts (16, (29) (30) (31) . Since Wnt5a expression inversely correlated with expression of Ki67 ( Figure 1E and Table 1 
activated oncogenes (such as oncogenic-RAS) is a standard approach for inducing senescence in a synchronized manner in primary human cells (1, 2, 19, 20) . Indeed, ectopic expression of oncogenic H-RAS G12V induced senescence of primary HOSE cells, as evident by an increase in SA-β-gal activity, a universal marker of cellular senescence ( Figure S3A-B) . 0.004). In addition, we also observed an increase in the number and size of PML bodies in the Wnt5a restored OVCAR5 EOC cells ( Figure 5A ), which are also established markers of cellular senescence (35, 38) . Similarly, we observed activation of the HIRA/PML pathway by Wnt5a restoration in PEO1 human EOC cells ( Figure S4A-B) , suggesting that the observed effects are not cell line specific. Together, we conclude that Wnt5a reconstitution activates the HIRA/PML senescence pathway.
The p53 and pRB tumor suppressor pathways play a key role in regulating senescence (1) . Thus, we sought to determine whether activation of the HIRA/PML pathway depends upon the p53 and pRB pathways. Interestingly, p16
INK4a
, the upstream repressor of pRB, is deleted in OVCAR5 human EOC cell line (39) . In addition, the levels of total phosphorylated pRB were not decreased by Wnt5a, while the levels of cyclin D1/CKD4-mediated Serine 780 phosphorylation on pRB (pRBpS780) were decreased by Wnt5a (40) (Figure 5C-D) . Further, p53 is null in OVCAR5 cells (41) . We conclude that activation of the HIRA/PML pathway is independent of the p53 and p16
INK4a .
We next sought to determine whether Wnt5a restoration induces SA-β-gal activity, a universal marker of cellular senescence (1). Indeed, SA-β-gal activity was notably induced by We next sought to determine whether Wnt5a would mediate growth inhibition and induce senescence in vivo in an orthotopic EOC model in immuno-compromised mice. A luciferase gene was retrovirally transduced into control or Wnt5a reconstituted OVCAR5 cells to monitor the cell growth in vivo via non-invasive imaging. These cells were injected unilaterally into the bursa sac covering the ovary in female immuno-compromised mice (n = 6 for each of the groups) ( Figure S5 ). Tumor growth was monitored every 5 days starting at day 10 post-injection by measuring luciferase activity, and the growth of the tumor was followed for a total of 30 days. to be an alternative approach. Interestingly, it has been previously reported that a Wnt5a-derived hexapeptide is sufficient to restore Wnt5a signaling both in vitro and in vivo in xenograft models of breast cancer (44) . It would be interesting to test whether the Wnt5a-derived hexapeptide will be sufficient to reconstitute Wnt5a signaling and drive senescence of EOC cells. Our data suggest that cellular senescence is a potential target for developing EOC therapeutics. In addition, these data imply that restoration of Wnt5a signaling represents a potential novel strategy to drive senescence of EOC cells.
This study is the first to demonstrate a role for Wnt5a in regulating senescence. We demonstrated that Wnt5a activated the senescence-promoting HIRA/PML pathway in human EOC cells (Figure 5A and S4A) . In primary human cells, activation of HIRA/PML pathway is sufficient to drive senescence by facilitating epigenetic silencing of proliferation-promoting genes (such as E2F target genes) (19 
HIRA/PML senescence pathway can be reactivated to drive senescence of human cancer cells.
Further studies are warranted to elucidate the molecular basis by which Wnt5a restoration and activation of HIRA/PML pathway drive cellular senescence in human EOC cells.
Interestingly, senescence induced by Wnt5a restoration in human EOC cells was independent of both the p53 and p16
INK4a tumor suppressors, which implies that EOC cells that lack p53 and p16I NK4a retain the capacity to undergo senescence via HIRA/PML pathway through suppressing the canonical Wnt signaling. This is consistent with previous reports
showing that cancer cells that lack p53 and pRB retain the capacity to undergo senescence when treated with anticancer agents or ionizing radiation (6) . Notably, although the levels of total phosphorylated pRB were not decreased by Wnt5a, we observed a decrease in the levels of pRBpS780 that is mediated by cyclin D1/CDK4 ( Figure 5C-D) . Future studies will determine whether the decrease in pRBpS780 levels plays a role in regulating senescence of human EOC cells.
Expression of Wnt5a is altered in many types of cancers (45) . For example, in melanoma, Wnt5a overexpression correlates with cancer progression and a higher tumor stage (16) . However, in colorectal and esophageal squamous cell carcinomas, Wnt5a has been described to be a tumor suppressor and was frequently silenced by promoter hypermethylation (16, 46) . Consistently, we also observed Wnt5a promoter hypermethylation in a number of human EOC cell lines in which Wnt5a is downregulated ( Figure 2 and Table S1 ). This result is consistent with the idea that Wnt5a promoter hypermethylation contributes to Wnt5a downregulation in human EOC cells. 
Wnt5a function is highly dependent on cellular context (45) . For example, the cellular Wnt receptor/co-receptor context dictates the downstream signaling pathways upon the binding of Wnt5a, which include activating non-canonical Wnt signaling or antagonizing canonical Wnt/β-catenin signaling (47) . These reports illustrate that Wnt5a expression and its resulting activity are cell type and context dependent. The Wnt receptor/co-receptor profile in EOC cells is currently unknown, and our future studies will elucidate the mechanism by which Wnt5a
antagonizes Wnt/ β-catenin signaling in human EOC cells. Regardless, our data show that Wnt5a downregulation is an independent predictor for overall survival in EOC patients. In contrast, two other studies showed that higher Wnt5a expression predicts poor survival in EOC patients (48, 49) . The basis for this discrepancy remains to be elucidated. An explanation may be that our study included more cases than the other two studies (130 EOC cases in our study vs.
cases in the study by Badiglian et al or 63 cases in the study by Peng et al).
It may also be due to the difference in the composition of Type I and Type II cases in this study compared to the other two studies. The vast majority of EOC cases in this study are of Type II high-grade serous subtypes. Consistently, our data showed that there is a difference in Wnt5a expression between Type I and Type II EOC (Table 1, 
